Retinoblastoma 1 (RB1) antibody

Antigen: Retinoblastoma 1 (RB1)

Synonyms: RB, pRb, OSRC, pp110, p105-Rb, Rb, Rb-1, RB1, RB11, PP110, P105-RB

Clonality: Monoclonal

Host: Rabbit

Reactivity: Human

Conjugate: Un-conjugated

Application: Western Blotting (WB)

Certificates: ISO 9001:2008

Catalog no.: ABIN650375

Additional Information

Alternative name: Rb

Gene ID: 5925

UniProt: P06400

Immunogen: A synthetic peptide corresponding to residues in human Rb was used as an immunogen.

Description: Other names: RB1, Retinoblastoma-associated protein, pp110,p105-Rb

Characteristics: Rabbit Monoclonal

Specificity: A synthetic peptide corresponding to residues in human Rb was used as an immunogen.

Molecular Weight: 110 kDA

Comments:

Background: Retinoblastoma tumor suppressor protein (Rb) is associated with DNA binding activity and is thought to play a significant role in controlling cell cycle progression during tumor growth (1, 2). Cell cycle-dependent phosphorylation by cdk's inhibits Rb binding, thus allowing cell cycle progression (3). Rb inactivation and cell cycle progression likely requires first phosphorylation by cyclin D-cdk4/6 followed by cyclin E-cdk2 phosphorylation (4).

Application Details

Application Notes: The suggested dilution is: WB: ~~ 1:1000~2000

Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.

Storage: Rb Antibody can be stored at -20°C for up to 12 months from time of receipt.

Research Area: Translation Factors, Signaling, Phospho-specific antibodies, Protein Modifications, Cancer, Transcription Factors, Chromatin, Cell Structure

Restrictions: For Research Use only

Publications

Product: Sherr: "Cancer cell cycles." in: Science (New York, N.Y.), Vol. 274, Issue 5293, pp. 1672-7, 1997 (PubMed).

Knudsen, Wang: "Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation." in: Molecular and cellular biology, Vol. 17, Issue 10, pp. 5771-83, 1997 (PubMed).

Lundberg, Weinberg: "Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes." in: Molecular and cellular biology, Vol. 18, Issue 2, pp. 753-61, 1998 (PubMed).